NASDAQ:GLTO

Galecto Stock Insider Trading

Healthcare > Biotechnology

Buy GLTO

*Your capital is at risk

$22.20

+0 (+0%)

At Close: Jul 31, 2026

Galecto Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.92. In total, the insiders bought 30.6M and sold 7.52K GLTO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.92
● Buy	30.6M shares
● Sell	7.52K shares
85% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Nov 10, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.92. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (85% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 03, 2025 Buy	Common Stock M-Exempt	Firmani Lori Interim CFO	C-Suite Officer	726 Value: $4K
Jan 03, 2025 Buy	Restricted Stock Units M-Exempt	Firmani Lori Interim CFO	C-Suite Officer	726 Value: $4K
Jan 03, 2025 Buy	Stock Option (right to buy) A-Award	Firmani Lori Interim CFO	C-Suite Officer	5 000 Value: $28.5K
Jan 03, 2025 Sell	Common Stock S-Sale	Winslow Garrett General Counsel	Officer	471 Value: $3K
Jan 03, 2025 Buy	Common Stock M-Exempt	Winslow Garrett General Counsel	Officer	1 320 Value: $8K
Jan 03, 2025 Buy	Restricted Stock Units M-Exempt	Winslow Garrett General Counsel	Officer	1 320 Value: $8K
Jan 03, 2025 Buy	Stock Option (right to buy) A-Award	Winslow Garrett General Counsel	Officer	6 000 Value: $34.2K
Oct 11, 2024 Buy	Stock Option (right to buy) A-Award	Wechsler Amy B Director	Director	720 Value: $5K
Oct 11, 2024 Buy	Stock Option (right to buy) A-Award	Wechsler Amy B Director	Director	480 Value: $3K
Oct 11, 2024 Buy	Common Stock J-Other	Wechsler Amy B Insider	Other	0 Value: $0
Oct 11, 2024 Buy	Common Stock J-Other	Wechsler Amy B Insider	Other	0 Value: $0
Oct 11, 2024 Buy	Stock Option (right to buy) A-Award	Wechsler Amy B Director	Director	480 Value: $3K
Oct 11, 2024 Buy	Stock Option (right to buy) A-Award	Wechsler Amy B Director	Director	720 Value: $5K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Kronmiller Matthew EVP Strategy And Cbo	Officer	8 600 Value: $64.4K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Firmani Lori Interim CFO	C-Suite Officer	13 000 Value: $97.4K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Winslow Garrett General Counsel	Officer	15 600 Value: $116.8K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Schambye Hans T. Chief Executive Officer	CEO / President	44 100 Value: $330.3K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Schambye Hans T. Chief Executive Officer	CEO / President	44 100 Value: $330.3K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Winslow Garrett General Counsel	Officer	15 600 Value: $116.8K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Firmani Lori Interim CFO	C-Suite Officer	13 000 Value: $97.4K
Oct 09, 2024 Buy	Stock Option (right to buy) A-Award	Kronmiller Matthew EVP Strategy And Cbo	Officer	8 600 Value: $64.4K
Oct 07, 2024 Buy	Common Stock J-Other	Kronmiller Matthew Insider	Other	0 Value: $0
Oct 07, 2024 Buy	Common Stock J-Other	Kronmiller Matthew Insider	Other	0 Value: $0
Aug 12, 2024 Buy	Stock Option (right to buy)	Firmani Lori Interim CFO	C-Suite Officer	40 000 Value: $520.0K
Aug 12, 2024 Buy	Stock Option (right to buy)	Firmani Lori Interim CFO	C-Suite Officer	37 500 Value: $121.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GALECTO, INC.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a ...

Read Full Profile Here